STAT+: Generative AI is supposed to save doctors from burnout. New data show it needs more training
After stratospheric levels of hype, early evidence may be bringing generative artificial intelligence down to…
Category: STAT+
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
LONDON — Claire Booth, a gene therapy researcher in London, had hoped that a biotech…
STAT+: Equity, technology, and costs top of mind for life science’s leaders
Physicians, researchers, CEOs, reporters, and more gathered in downtown Boston Wednesday night to celebrate STAT’s…
STAT+: Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
After months of deliberation, the Colombian government has issued a compulsory license for an HIV…
STAT+: FTC’s noncompete ban immediately challenged in Texas district lawsuit
Vindication came swiftly on Wednesday for those who predicted legal challenges to the Federal Trade…
STAT+: Takeda is fourth big company to leave BIO since December
WASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure…
STAT+: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses….
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
Two years after biosimilars became available in the U.S., a higher proportion of patients using…
STAT+: New studies suggest GLP-1 health care costs have only begun to climb
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they’re set to…
STAT+: HCA to expand the use of AI tool to automate clinical documentation in ER
HCA Healthcare, the largest for-profit hospital chain in the United States, is planning to expand…
STAT+: Novo Nordisk’s move to discontinue an insulin leaves patients to ‘pick up the pieces’
A year ago, when Novo Nordisk announced it would cut the price of multiple insulin…
STAT+: Anticompetitive hospital mergers skate by due to FTC’s shallow resources
Over the past two decades, hundreds of hospital mergers have escaped federal antitrust scrutiny and…
STAT+: FTC’s noncompete ban would force sweeping changes in health care, if it survives legal battle
The Federal Trade Commission approved a far-reaching noncompete ban Tuesday that could force sweeping changes…
STAT+: NIH postdocs will get a raise next year — but not as much as they hoped
The National Institutes of Health will raise the minimum salary for postdoctoral researchers to $61,008…
STAT+: Health care lobbying giants spent big as little got done in Congress
WASHINGTON — Congress did nothing this spring to rein in how pharmacy benefit managers operate,…
STAT+: Day One drug for common childhood brain tumor approved by FDA
Day One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one…
STAT+: The evidence grows: Prices spike after mergers between far-flung hospitals
The trend is clear: When hospitals in the same community merge, prices spike. The government…
STAT+: Pharmalittle: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Looking for signs of growth in Biogen’s earnings
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Accreditation agencies take on telehealth with new virtual care standards
In the early days of the pandemic, as social distancing forced patients out of doctors’…
Opinion: STAT+: Use evidence to support early coverage of gene therapy after accelerated approval
Gene editing and therapy to replace missing or defective genes is one of the most…
.jpg)
STAT+: In a scientific first, researchers use CRISPR base editing to treat liver disease in fetal monkeys
The ambitious idea of using CRISPR to cure genetic diseases before birth is one step…
STAT+: ‘Devalued, disempowered, and unseen’: Mass General Brigham doctors react to latest merger step
Discontent among Mass General Brigham doctors had been at a slow burn for years. But…
STAT+: Novo Nordisk’s growth plan
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about an OptumRx contract, 340B dispute resolution, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: How a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth
Makena, once the only available treatment to prevent preterm birth, has had its share of…
STAT+: Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: New antibiotics were underprescribed for hard-to-treat infections, study finds
Although U.S. regulators approved several new antibiotics for combating hard-to-treat bacteria during a recent five-year…
STAT+: Medicare official says breakthrough device reimbursement rule coming in early summer
WASHINGTON — A federal rule aiming to make reimbursement for breakthrough devices easier is slated…
Opinion: STAT+: How AI can help satisfy FDA’s drug, device diversity requirements
The Food and Drug Omnibus Reform Act of 2022 (FDORA), which was passed as part…
STAT+: Elevance’s private equity deal will form $4 billion primary care company
These days, the surefire way to get ahead in health insurance is to become a…
.jpg)
STAT+: Dana-Farber retracts string of studies in systematic review of data integrity
An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string…
STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Taking stock of the frenzied push into autoimmune disease
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases
A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for…
STAT+: 23andme CEO Anne Wojcicki moves to take company private
After a tumultuous experience on the public markets, 23andMe CEO Anne Wojcicki is moving to…
STAT+: Cancer vaccine startup launches with $54 million, Spark veteran as CEO
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched…
STAT+: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new…
STAT+: Cerevel drug for Parkinson’s disease improved symptom control in trial
Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its drug for Parkinson’s…
STAT+: Microsoft is selling AI in health care, and helping to set its standards. Is that a problem?
For a company moving as quickly as possible to build artificial intelligence into everything —…
STAT+: How BIO CEO’s cozy relationship with WuXi soured
WASHINGTON — In the photo, the two men are grinning widely: the CEO of WuXi Biologics…
STAT+: The next frontier in data privacy? Your brain
Consumer neurotechnology is booming. You can buy a funky-looking headband for $500 on the internet…
STAT+: Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported positive results of its obesity drug Zepbound in obstructive sleep apnea, giving…
Teladoc became a household name under Jason Gorevic. Investors wanted more
At the J.P. Morgan Healthcare Conference in January, Teladoc CEO Jason Gorevic dismissed the growing…
STAT+: Hospital price transparency rules are seeding a new crop of health tech startups
Federal rules forcing hospitals and insurers to post rates for medical procedures have taken effect,…
STAT+: UnitedHealth skips hearing in the wake of Change cyberattack, triggering call for subpoena
In the first federal hearing focused on the massive cyberattack on Change Healthcare, lawmakers had…
STAT+: UnitedHealth reaffirms financial outlook despite up to $1.6 billion hit from Change Healthcare cyberattack
Hospitals and medical groups say they’re still reeling from the effects of the cyberattack on…